Market Size

The oncology precision medicine market, valued at USD 166 billion in 2025, is project to reach USD 185 billion in 2026 and USD 364 billion by 2035, representing a CAGR of 7.8% during the forecast period 2026 to 2035.

Global Oncology Precision Medicine Market 2018-2035

See What’s in the Full Report–Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size & Trends

In terms of type of cancer targeted, the blood / hematologic cancer segment holds the highest share (~25%) of the market.
With regards to route of administration, the intravenous route of administration segment dominates the global market.
Based on the type of molecule, the biologics segment holds the largest market share (nearly 60%) in 2026.
With respect to drug class, kinase inhibitor captures the highest share (53%) in 2026.
In terms of key geographical regions, North America captures the majority of the market share. Notably, Asia-Pacific is anticipated to grow at a faster pace in the near future.

Key Market Statistics

Market Size in 2026: $185 Billion
Estimated Market Size in 2035: $364 Billion
CAGR (2026-2035): 7.8%
North America: Largest market in 2026
Asia-Pacific: Fastest growing region

Market Overview

Cancer is recognized as one of the deadliest diseases due to the high prevalence and mortality rates across the globe. According to the World Health Organization, in the year 2020, the global cancer burden was estimated to be 20 million new cases and 10 million deaths, annually, and is anticipated to rise by nearly 60%, by 2040. The key factors contributing to the growing prevalence and pathogenesis of cancer include alcohol intake, obesity, viral infections, radiation and chemical exposure.

Currently, there are several conventional approaches, including surgery, radiation therapy, and chemotherapy that are used for the treatment of cancer. In addition, there are several nonconventional or complementary therapeutic methods that are being employed in cancer treatment, such as hormone therapy, immunotherapy and nanotherapy. However, these approaches have been found to be incompetent for dealing with intrinsic carcinogenic genetic abnormalities, which can arise from patient-specific mutations in oncogenes, tumor suppressor genes and DNA repair genes.

In order to address abovementioned limitation of existing treatment options, the concept of precision medicine, often known as personalized medicine, has emerged as a possible solution, which utilizes genomic knowledge to develop gene-targeted therapeutics.

Oncology Precision Medicine Market, Clinical Trial Analysis

The development process of precision medicine involves the study of tumor features, genetic data, lifestyle of patients and environmental effects to provide tailored medicines, which hold significant potential in treating oncological disorders by shifting away from a one-size-fits-all approach. Individuals with a family history of certain types of cancer are more likely to be at risk of inheriting the condition.

In such cases, precision oncology aids individuals to take genetic testing and become aware of the associated risk. Further, prior screening for cancer can help in detection of the disease at an early stage, providing a much better chance of successful treatment.

It is worth highlighting that there are number of precision cancer centers, such as MD Anderson Cancer Center in US, Memorial Sloan Kettering Cancer Center in New York and Mayo Clinic Cancer Center in US, that offer advanced technologies and treatments that are suitable for patients with rare or difficult-to-treat cancers. Further, the oncology precision medicines have shown high efficiency during clinical trials due to which the participation of volunteers in such trials has increased. This has resulted in a higher patient pool in clinical trials, helping the researchers in better decision making for the evaluated drug or technology. With continuous research efforts and innovation in this field, it is anticipated that the adoption of such targeted drugs will increase significantly, driving the oncology precision medicine market growth during the forecast period.

Recent Developments

In April 2026, Acurion, an oncology precision medicine company developing its OncoGaze platform to analyze genomic biomarkers from routine pathology samples, closed an oversubscribed seed round raising USD 4.3 million.
In March 2026, Silexion Therapeutics received Israeli regulatory approval to advance its RNAi based oncology precision medicine candidate SIL204, an investigational KRAS targeted therapy, into a combined Phase 2/3 trial for KRAS driven cancers.

Oncology Precision Medicine Market, Case Study on OPM Assay Kits

Oncology Precision Medicine Market Trends

Increase in Partnership: The partnerships have enabled the stakeholders to enhance their existing capabilities and drug portfolios and strengthen their presence in the oncology precision medicine domain. Drug licensing agreements, clinical trial agreements, and research and development agreements are the most common types of partnerships signed by stakeholders in the precision medicine in oncology domain. Most of these partnerships are focused on targeting cancers, including gastrointestinal cancer (23%), lung cancer (23%), hematologic cancer and breast cancer (15%, each). In parallel, EZH2 inhibitors target an epigenetic regulator implicated in selected hematological and solid malignancies.
Clinical Trial Activity: There has been a notable rise in the number of clinical trials evaluating precision medicines for oncology. Around 6,500 clinical trials related to precision medicine in oncology have been registered in the past six years, indicating substantial research in this domain. Among these, about 60% of these clinical trials are actively recruiting to evaluate drugs for various types of cancer targeted. Across related applications, DNA damage response targets repair pathway vulnerabilities to support biomarker-led precision oncology strategies.

Pay Only for What You Need–The Best Way to Optimize

Industry Experts

The oncology precision medicine market report features detailed transcripts of interviews held with the following industry stakeholders (arranged on the basis of designation):

Chief Scientific Officer and Founder, Very Small Company, US
Vice President, Mid-sized Company, US

Market Share by Target Cancer

This section includes segment of oncology precision medicine market based on target cancer, including bladder cancer, blood / hematologic cancer, breast cancer, cervical cancer, gastrointestinal cancer, head and neck squamous cell cancer, lung cancer, skin cancer and others.
Among these the blood / hematologic cancer holds the maximum share (~55%) in the current precision oncology market. This can be attributed to the high incidence of blood / hematologic cancer, accounting for around 1.25 million cases worldwide per year.
As per our precision oncology market analysis, gastrointestinal cancer is estimated to grow at the highest CAGR (>10%) till 2035.

Market Share by Route of Administration

The global oncology precision medicine market is categorized into oral and intravenous route of administration.
Owing to their comfortable and convenient nature, the segment for oral route of administration is likely to grow at a higher CAGR (9.18%) as compared to other routes of administration in the coming years.

Oncology Precision Medicine Market by Route of Administration 2025

Market Share by Drug Class

This segment includes the segmentation of global oncology precision medicine market across different drug classes, such as kinase inhibitors, enzyme inhibitors, immune checkpoint inhibitors and others.
The kinase inhibitor drug class segment occupies the highest share and is expected to witness substantial growth in the coming years. It is worth noting that majority of kinase inhibitors target mutated protein growth factors, such as EGFR and FGFR.

Market Share by Type of Molecule

The global oncology precision medicine market is segmented into small molecules and biologics. The small molecules segment occupies the highest share and is expected to remain dominant during the forecast period.
This can be primarily attributed to the fact that small molecules can pass the cellular membranes and disrupts the intracellular protein-protein interactions. This interference affects the crucial cellular processes, such as signalling pathways, protein functions and ultimately impact the normal functioning of the cell.

Unlock Deeper Insights–Schedule Your Personalized Workshop Today!

Oncology Precision Medicine Market by Molecule Type 2025 to 2035

Market Share by Key Geographical Regions

It is worth highlighting that North America captures 42% of the current total oncology precision medicine market. Further, oncology precision medicine market in Asia-Pacific is expected to grow with a CAGR of more than 14.37%.
This can be attributed to the fact that Asian countries, including China, Japan, Korea and India have a growing economy, and thus require low-cost investment for conducting clinical trials. Further, several investments and initiatives taken by government authorities in the Asian countries promote the oncology precision medicine market.
The detailed methodology across the global oncology precision medicine market and revenue generated across various segments is available in the full report.

Key Market Insights

Competitive Landscape of Oncology Precision Medicine Developers

The oncology precision medicine is among the most promising domains in the healthcare industry. Currently, over 125 precision medicine oncology companies are involved in developing various personalized medicines for oncology. In addition, around 145 personalized medicines have been commercialized for targeting various cancer indications. Further, more than 100 personalized medicines targeting oncological disorders are in the early (pre-clinical and discovery phase) stages of development.

Regional Analysis: North America Emerged as the Hub of Oncology Precision Medicine; Europe to be the Fastest Growing Market

In 2026, North America is anticipated to capture close to 42% market share of the overall oncology precision medicine market.

In recent years, demand for oncology precision medicine has witnessed a tremendous increase in North America.

Further, it is worth highlighting that, owing to the rising demand for oncology precision medicines, market in Asia is likely to grow at a higher CAGR as compared to other regions in the coming years.

Want Information on Specific Region/Segment?

Market Segmentation Insights

Key Report Attribute	Details
Historical Trend	Since 2018
Forecast Period	Till 2035
Market Size 2026	USD 185 Billion
Market Size 2035	USD 364 Billion
CAGR (Till 2035)	7.8%
Type of Cancer Targeted	Bladder Cancer Blood / Hematologic Cancer Breast Cancer Cervical Cancer Gastrointestinal Cancer Head and Neck Squamous Cell Cancer Lung Cancer Skin Cancer Others
Route of Administration	Oral Intravenous Others
Type of Molecule	Small Molecules Biologics
Drug Class	Kinase Inhibitors Enzyme Inhibitors Immune Checkpoint Inhibitors Others
Leading Drug Developers	Merck Pfizer AstraZeneca Johnson $ Johnson Innovative Medicine Genentech
Key Geographical Regions	North America (US, Canada) Europe (France, Germany, Italy, Spain and UK) Asia (China, Japan, Korea and India) Middle East and North Africa (UAE, Israel, Qatar and Rest of Middle East and North Africa) Latin America (Brazil, Argentina, Chile and Rest of Latin America)
Key Players	AbbVie Anticancer Bioscience Astellas Pharma Astrazeneca Bayer Blueprint Medicines Bristol Myers Squibb Eli Lilly Erasca Genentech GlaxoSmithKline Hutchmed IDEAYA Biosciences Jiangsu Hengrui Pharmaceuticals Johnson & Johnson Innovative Medicine Merck Novartis Pfizer Repare Therapeutics Roche Seagen SpringWorks Therapeutics Takeda Pharmaceutical VERAXA Biotech GmbH VRise Therapeutics (Full list of >125 precision medicine oncology companies captured in the market landscape analysis of the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Market Landscape Partnerships and Collaborations Clinical Trial Analysis Case Study: Oncology Precision Medicine Assay Kits Market Forecast and Opportunity Analysis

+ 1. PREFACE

1.1. Introduction

1.2. Market Share Insights

1.3. Key Market Insights

1.4. Report Coverage

1.5. Key Questions Answered

1.6. Chapter Outlines

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.3. Project Methodology

2.4. Forecast Methodology

2.5. Robust Quality Control

2.6. Key Market Segmentations

2.7. Key Considerations

2.7.1. Demographics

2.7.2. Economic Factors

2.7.3. Government Regulations

2.7.4. Supply Chain

2.7.5. COVID Impact / Related Factors

2.7.6. Market Access

2.7.7. Healthcare Policies

2.7.8. Industry Consolidation

+ 3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview

3.2. Market Dynamics

3.2.1. Time Period

3.2.1.1. Historical Trends

3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage

3.2.2.1. Overview of Major Currencies Affecting the Market

3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact

3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market

3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession

3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt

3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation

3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

3.2.5.2. Potential Impact of Inflation on the Market Evolution

+ 4. EXECUTIVE SUMMARY

+ 5. INTRODUCTION

5.1. Chapter Overview

5.2. Precision Medicine

5.2.1. Evolution of Precision Medicine

5.3. Oncology Precision Medicine

5.3.1. Oncology Precision Medicine over Traditional Cancer Medicine

5.3.2. Steps Involved in Developing Oncology Precision Medicine

5.3.3. Advantages Associated with Oncology Precision Medicine

5.3.3.1. Benefits to the Patients

5.3.3.2. Benefits to the Healthcare Providers

5.3.3.3. Benefits to the Cancer Researchers

5.3.4. Challenges Associated with Oncology Precision Medicines

5.3.5. Future Perspectives

+ 6. ONCOLOGY PRECISION MEDICINE: MARKET LANDSCAPE

6.1. Chapter Overview

6.2. Oncology Precision Medicine: Commercialized and Clinical Stage Drugs Market Landscape

6.2.1. Analysis by Stage of Development

6.2.2. Analysis by Approval Body

6.2.3. Analysis by Approval Region

6.2.4. Analysis by Drug Designation

6.2.5. Analysis by Type of Molecule

6.2.6. Analysis by Drug Class

6.2.7. Analysis by Route of Administration

6.2.8. Analysis by Dosage Regimen

6.2.9. Analysis by Patient Population

6.2.10. Analysis by Type of Cancer Targeted

6.2.11. Analysis by Stage of Development and Type of Cancer Targeted

6.3. Oncology Precision Medicine: Preclinical and Discovery Stage Drugs Market Landscape

6.3.1. Analysis by Stage of Development

6.3.2. Analysis by Type of Molecule

6.3.3. Analysis by Drug Class

6.3.4. Analysis by Type of Cancer Targeted

6.4. Oncology Precision Medicine: Developer Landscape

6.4.1. Analysis by Year of Establishment

6.4.2. Analysis by Company Size

6.4.3. Analysis by Location of Headquarters (Region)

6.4.4. Analysis by Location of Headquarters (Country)

6.4.5. Analysis by Company Size and Location of Headquarters (Region)

6.4.6. Most Active Players: Analysis by Number of Oncology Precision Medicines

+ 7. DETAILED COMPANY PROFILES

7.1. Chapter Overview

7.2. AstraZeneca

7.2.1. Company Overview

7.2.2. Financial Information

7.2.3. Oncology Precision Medicine Portfolio

7.2.4. Recent Developments and Future Outlook

7.3. Genentech

7.3.1. Company Overview

7.3.2. Financial Information

7.3.3. Oncology Precision Medicine Portfolio

7.3.4. Recent Developments and Future Outlook

7.4. Jiangsu Hengrui Pharmaceuticals

7.4.1. Company Overview

7.4.2. Oncology Precision Medicine Portfolio

7.4.3. Recent Developments and Future Outlook

7.5. Johnson & Johnson Innovative Medicine

7.5.1. Company Overview

7.5.2. Financial Information

7.5.3. Oncology Precision Medicine Portfolio

7.5.4. Recent Developments and Future Outlook

7.6. Novartis

7.6.1. Company Overview

7.6.2. Financial Information

7.6.3. Oncology Precision Medicine Portfolio

7.6.4. Recent Developments and Future Outlook

7.7. Pfizer

7.7.1. Company Overview

7.7.2. Financial Information

7.7.3. Oncology Precision Medicine Portfolio

7.7.4. Recent Developments and Future Outlook

7.8. SpringWorks Therapeutics

7.8.1. Company Overview

7.8.2. Oncology Precision Medicine Portfolio

7.8.3. Recent Developments and Future Outlook

+ 8. SHORT COMPANY PROFILES

8.1. Chapter Overview

8.2. AbbVie

8.3. Anticancer Bioscience

8.4. Astellas Pharma

8.5. Bayer

8.6. Blueprint Medicines

8.7. Bristol Myers Squibb

8.8. Eli Lilly

8.9. Erasca

8.10. GlaxoSmithKline

8.11. Hutchmed

8.12. IDEAYA Biosciences

8.13. Merck

8.14. Repare Therapeutics

8.15. Roche

8.16. Seagen

8.17. Takeda Pharmaceutical

8.18. VERAXA Biotech

8.19. VRise Therapeutics

+ 9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview

9.2. Partnership Models

9.3. Oncology Precision Medicine: Partnerships and Collaborations

9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership

9.3.3. Analysis by Year and Type of Partnership

9.3.4. Analysis by Type of Partner

9.3.5. Analysis by Drug Involved

9.3.6. Analysis by Type of Cancer Targeted

9.3.7. Most Active Players: Analysis by Number of Partnerships

9.3.8. Analysis by Geography

9.3.8.1. Local and International Agreements

9.3.8.2. Intracontinental and Intercontinental Agreements

+ 10. CLINICAL TRIAL ANALYSIS

10.1. Chapter Overview

10.2. Scope and Methodology

10.3. Oncology Precision Medicine: Clinical Trial Analysis

10.3.1. Analysis by Trial Registration Year

10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year

10.3.3. Analysis by Trial Phase

10.3.4. Analysis of Number of Patients Enrolled by Trial Phase

10.3.5. Analysis by Trial Registration Year and Trial Phase

10.3.6. Analysis by Trial Status

10.3.7. Analysis by Trial Registration Year and Trial Status

10.3.8. Analysis by Target Patient Population

10.3.9. Analysis by Patient Gender

10.3.10. Analysis by Type of Cancer Targeted

10.3.11. Analysis by Type of Sponsor / Collaborator

10.3.12. Analysis by Study Design

10.3.12.1. Analysis by Type of Trial Masking

10.3.12.2. Analysis by Type of Intervention Model

10.3.12.3. Analysis by Type of Intervention

10.3.12.4. Analysis by Trial Purpose

10.3.13. Most Active Sponsors / Collaborators: Analysis by Number of Clinical Trials

10.3.13.1. Analysis by Leading Industry Players

10.3.13.2. Analysis by Leading Non-Industry Players

10.3.14. Word Cloud Analysis: Emerging Focus Areas

10.3.15. Analysis by Geography

10.3.15.1. Analysis of Clinical Trials by Geography

10.3.15.2. Analysis of Clinical Trials by Geography and Trial Status

10.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status

+ 11. CASE STUDY: ONCOLOGY PRECISION MEDICINE ASSAY KITS

11.1. Chapter Overview

11.2. Oncology Precision Medicine: Assay Kits

11.2.1. Analysis by Stage of Development

11.2.2. Analysis by Regulatory Certification / Compliance

11.2.3. Analysis by Regional Availability

11.2.4. Analysis by Type of Test

11.2.5. Analysis by Type of Sample Used

11.2.6. Analysis by Principle of Biomarker Detection

11.2.7. Analysis by Turnaround Time

11.2.8. Analysis by Type of Cancer Targeted

11.2.9. Analysis by Turnaround Time and Type of Cancer Targeted

11.2.10. Analysis by End-user

11.2.11. Analysis by Regional Availability and End-user

11.2.12. Analysis by Type of Cancer Targeted and End-user

11.3. Oncology Precision Medicine Assay Kits: Developer Landscape

11.3.1. Analysis by Year of Establishment

11.3.2. Analysis by Company Size

11.3.3. Analysis by Location of Headquarters (Region)

11.3.4. Analysis by Location of Headquarters (Country)

11.3.5. Analysis by Company Size and Location of Headquarters (Region)

11.3.6. Analysis by Business Model

11.3.7. Most Active Players: Analysis by Number of Oncology Precision Medicine Assay Kits

+ 12. CASE STUDY: TECHNOLOGIES USED IN PRECISION MEDICINE

12.1. Chapter Overview

12.2. Technologies Used in Precision Medicine

12.2.1. Next Generation Sequencing in Precision Medicine

12.2.2. Nanotechnology in Precision Medicine

12.2.3. Molecular Imaging Technologies in Precision Medicine

12.2.4. Omics Technologies in Precision Medicine

12.2.5. Artificial Intelligence (AI) in Precision Medicine

12.3. Conclusion

+ 13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

13.1. Chapter Overview

13.2. Market Drivers

13.3. Market Restraints

13.4. Market Opportunities

13.5. Market Challenges

13.6. Conclusion

+ 14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET

14.1. Chapter Overview

14.2. Assumptions and Methodology

14.3. Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)

14.4. Scenario Analysis

14.4.1. Conservative Scenario

14.4.2. Optimistic Scenario

14.5. Key Market Segmentations

+ 15. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF CANCER TARGETED

15.1. Chapter Overview

15.2. Key Assumptions and Methodology

15.3. Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035

15.3.1. Bladder Cancer: Forecasted Estimates (2023-2035)

15.3.2. Blood / Hematologic Cancer: Forecasted Estimates (2023-2035)

15.3.3. Breast Cancer: Forecasted Estimates (2023-2035)

15.3.4. Cervical Cancer: Forecasted Estimates (2023-2035)

15.3.5. Gastrointestinal Cancer: Forecasted Estimates (2023-2035)

15.3.6. Head and Neck Squamous Cell Cancer: Forecasted Estimates (2023-2035)

15.3.7. Lung Cancer: Forecasted Estimates (2023-2035)

15.3.8. Skin Cancer: Forecasted Estimates (2023-2035)

15.3.9. Other Cancers: Forecasted Estimates (2023-2035)

15.4. Data Triangulation and Validation

+ 16. ONCOLOGY PRECISION MEDICINE MARKET, BY ROUTE OF ADMINISTRATION

16.1. Chapter Overview

16.2. Key Assumptions and Methodology

16.3. Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035

16.3.1. Oral: Forecasted Estimates (2023-2035)

16.3.2. Intravenous: Forecasted Estimates (2023-2035)

16.3.3. Others: Forecasted Estimates (2023-2035)

16.4. Data Triangulation and Validation

+ 17. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF MOLECULE

17.1. Chapter Overview

17.2. Key Assumptions and Methodology

17.3. Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035

17.3.1. Small Molecules: Forecasted Estimates (2023-2035)

17.3.2. Biologics: Forecasted Estimates (2023-2035)

17.4. Data Triangulation and Validation

+ 18. ONCOLOGY PRECISION MEDICINE MARKET, BY DRUG CLASS

18.1. Chapter Overview

18.2. Key Assumptions and Methodology

18.3. Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035

18.3.1. Kinase Inhibitors: Forecasted Estimates (2023-2035)

18.3.2. Enzyme Inhibitors: Forecasted Estimates (2023-2035)

18.3.3. Immune Checkpoint Inhibitors: Forecasted Estimates (2023-2035)

18.3.4. Others: Forecasted Estimates (2023-2035)

18.4. Data Triangulation and Validation

+ 19. ONCOLOGY PRECISION MEDICINE MARKET, BY KEY GEOGRAPHICAL REGIONS

19.1. Chapter Overview

19.2. Key Assumptions and Methodology

19.3. Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035

19.3.1. North America: Forecasted Estimates (2023-2035)

19.3.1.1. US: Forecasted Estimates (2023-2035)

19.3.1.2. Canada: Forecasted Estimates (2023-2035)

19.3.2. Europe: Forecasted Estimates (2023-2035)

19.3.2.1. France: Forecasted Estimates (2023-2035)

19.3.2.2. Germany: Forecasted Estimates (2023-2035)

19.3.2.3. Italy: Forecasted Estimates (2023-2035)

19.3.2.4. Spain: Forecasted Estimates (2023-2035)

19.3.2.5. UK: Forecasted Estimates (2023-2035)

19.3.3. Asia: Forecasted Estimates (2023-2035)

19.3.3.1. China: Forecasted Estimates (2023-2035)

19.3.3.2. Japan: Forecasted Estimates (2023-2035)

19.3.3.3. Korea: Forecasted Estimates (2023-2035)

19.3.3.4. India: Forecasted Estimates (2023-2035)

19.3.4. Middle East and North Africa: Forecasted Estimates (2023-2035)

19.3.4.1. UAE: Forecasted Estimates (2023-2035)

19.3.4.2. Israel: Forecasted Estimates (2023-2035)

19.3.4.3. Qatar: Forecasted Estimates (2023-2035)

19.3.4.4. Rest of Middle east and North Africa: Forecasted Estimates (2023-2035)

19.3.5. Latin America: Forecasted Estimates (2023-2035)

19.3.5.1. Brazil: Forecasted Estimates (2023-2035)

19.3.5.2. Argentina: Forecasted Estimates (2023-2035)

19.3.5.3. Chile: Forecasted Estimates (2023-2035)

19.3.5.4. Rest of Latin America: Forecasted Estimates (2023-2035)

19.4. Data Triangulation and Validation

+ 20. ONCOLOGY PRECISION MEDICINE MARKET, SALES FORECAST OF DRUGS

20.1. Chapter Overview

20.2. Key Assumptions and Methodology

20.3. Blockbuster Commercialzied Oncology Precision Medicine Market: Sales Forecast

20.3.1. ADCETRIS® Sales Forecast

20.3.2. Alecensa® Sales Forecast

20.3.3. ALUNBRIG® Sales Forecast

20.3.4. Avastin® Sales Forecast

20.3.5. Ayvakit® Sales Forecast

20.3.6. Braftovi®+ Mektovi® Sales Forecast

20.3.7. BRUKINSA® Sales Forecast

20.3.8. CALQUENCE® Sales Forecast

20.3.9. DARZALEX® Sales Forecast

20.3.10. Elunate® Sales Forecast

20.3.11. Empliciti® Sales Forecast

20.3.12. Enhertu® Sales Forecast

20.3.13. IBRANCE® Sales Forecast

20.3.14. ICLUSIG® Sales Forecast

20.3.15. IMBRUVICA® Sales Forecast

20.3.16. IMFINZI® Sales Forecast

20.3.17. INLYTA® Sales Forecast

20.3.18. Keytruda® Sales Forecast

20.3.19. Kadcyla® Sales Forecast

20.3.20. LENVIMA® / KISPLYX® Sales Forecast

20.3.21. Lumakras® / Lumykras® Sales Forecast

20.3.22. Mekinist® Sales Forecast

20.3.23. NERLYNX® Sales Forecast

20.3.24. NINLARO® Sales Forecast

20.3.25. Opdivo® Sales Forecast

20.3.26. Padcev® Sales Forecast

20.3.27. Piqray® Sales Forecast

20.3.28. Sprycel® Sales Forecast

20.3.29. Tabrecta® Sales Forecast

20.3.30. Tagrisso® Sales Forecast

20.3.31. Tasigna® Sales Forecast

20.3.32. Tecentriq® Sales Forecast

20.3.33. VENCLEXTA® Sales Forecast

20.3.34. Verzenio® / Verzenios Sales Forecast

20.3.35. Xospata® Sales Forecast

20.3.36. Xtandi® Sales Forecast

20.3.37. ZEJULA® Sales Forecast

20.4. NDA-filed Oncology Precision Medicine Market: Sales Forecast

20.4.1. Apatinib / Rivoceranib Sales Forecast

20.4.2. Elunate® Sales Forecast

20.5. Phase III Oncology Precision Medicine Market: Sales Forecast

20.5.1. Darovasertib / IDE196 Sales Forecast

20.5.1.1. Darovasertib / IDE196 Regional Sales Forecast

20.5.2. Elenestinib / BLU-263 Sales Forecast

20.5.2.1. Elenestinib / BLU-263 Regional Sales Forecast

20.5.3. Elunate® Sales Forecast

20.5.3.1. Elunate® Sales Forecast by Type of Cancer Targeted

20.5.3.2. Elunate® Regional Sales Forecast

20.5.4. ORPATHYS® Sales Forecast

20.5.4.1. ORPATHYS® Regional Sales Forecast

20.5.5. Pyrotinib Sales Forecast

20.5.5.1. Pyrotinib Sales Forecast by Type of Cancer Targeted

20.5.5.2. Pyrotinib Regional Sales Forecast

20.5.6. SYD985 / (Vic-) trastuzumab duocarmazine) Sales Forecast

20.5.6.1. SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast

20.5.7. ZOLINZA® Sales Forecast

20.5.7.1. ZOLINZA® Regional Sales Forecast

+ 21. ONCOLOGY PRECISION MEDICINE MARKET, BY LEADING DRUG DEVELOPERS

21.1. Chapter Overview

21.2. Key Assumptions and Methodology

21.3. Oncology Precision Medicine Market: Distribution by Leading Drug Developers

21.4. Data Triangulation and Validattion

+ 22. CONCLUSION

+ 23. EXECUTIVE INSIGHTS

23.1. Chapter Overview

23.2. Allarity Therapeutics

23.2.1. Company Snapshot

23.2.2. Interview Transcrip

23.3. Elephas

23.3.1. Company Snapshot

23.3.2. Interview Transcript

+ 24. APPENDIX 1: TABULATED DATA

+ 25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Research Assumptions

Figure 2.2 Research Methodology: Project Methodology

Figure 2.3 Research Methodology: Forecast Methodology

Figure 2.4 Research Methodology: Robust Quality Control

Figure 2.5 Research Methodology: Key Market Segmentations

Figure 4.1 Executive Summary: Market Landscape

Figure 4.2 Executive Summary: Partnerships and Collaborations

Figure 4.3 Executive Summary: Clinical Trial Analysis

Figure 4.4 Executive Summary: Market Forecast and Opportunity Analysis

Figure 5.1 Evolution of Precision Medicine

Figure 5.2 Oncology Precision Medicine over Traditional Cancer Medicine

Figure 5.3 Steps Involved in Developing Oncology Precision Medicines

Figure 5.4 Challenges Associated with Oncology Precision Medicines

Figure 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development

Figure 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body

Figure 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region

Figure 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation

Figure 6.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule

Figure 6.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class

Figure 6.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration

Figure 6.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen

Figure 6.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population

Figure 6.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted

Figure 6.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted

Figure 6.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development

Figure 6.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule

Figure 6.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class

Figure 6.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted

Figure 6.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment

Figure 6.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size

Figure 6.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)

Figure 6.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)

Figure 6.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)

Figure 6.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines

Figure 7.1 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Figure 7.2 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Figure 7.3 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Figure 7.4 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Figure 7.5 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023

Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023

Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner

Figure 9.5 Partnerships and Collaborations: Distribution by Drug Involved

Figure 9.6 Partnerships and Collaborations: Distribution by Type of Cancer Targeted

Figure 9.7 Most Active Players: Distribution by Number of Partnerships

Figure 9.8 Partnership and Collaborations: Local and International Agreements

Figure 9.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements

Figure 10.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023

Figure 10.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023

Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase

Figure 10.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase

Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018–2023

Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status

Figure 10.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018–2023

Figure 10.8 Clinical Trial Analysis: Distribution by Target Patient Population

Figure 10.9 Clinical Trial Analysis: Distribution by Patient Gender

Figure 10.10 Clinical Trial Analysis: Distribution by Type of Cancer Targeted

Figure 10.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Figure 10.12 Clinical Trial Analysis: Distribution by Type of Trial Masking

Figure 10.13 Clinical Trial Analysis: Distribution by Type of Intervention Model

Figure 10.14 Clinical Trial Analysis: Distribution by Type of Intervention

Figure 10.15 Clinical Trial Analysis: Distribution by Trial Purpose

Figure 10.16 Leading Industry Players: Distribution by Number of Clinical Trials

Figure 10.17 Leading Non-Industry Players: Distribution by Number of Clinical Trials

Figure 10.18 Word Cloud Analysis: Emerging Focus Areas

Figure 10.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography

Figure 10.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status

Figure 10.21 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status

Figure 11.1 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development

Figure 11.2 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance

Figure 11.3 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability

Figure 11.4 Oncology Precision Medicine Assay Kits: Distribution by Type of Test

Figure 11.5 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used

Figure 11.6 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection

Figure 11.7 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time

Figure 11.8 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted

Figure 11.9 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted

Figure 11.10 Oncology Precision Medicine Assay Kits: Distribution by End-user

Figure 11.11 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user

Figure 11.12 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user

Figure 11.13 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment

Figure 11.14 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size

Figure 11.15 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)

Figure 11.16 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)

Figure 11.17 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)

Figure 11.18 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model

Figure 11.19 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed

Figure 12.1 Applications of NGS in Oncology Precision Medicine

Figure 12.2 Applications of Nanotechnology in Oncology Precision Medicine

Figure 12.3 Applications of Molecular Imaging Technologies in Oncology Precision Medicine

Figure 12.4 Applications of Omics Technologies in Oncology Precision Medicine

Figure 12.5 Applications of AI in Oncology Precision Medicine

Figure 13.1 Oncology Precision Medicine: Market Drivers

Figure 13.2 Oncology Precision Medicine: Market Restraints

Figure 13.3 Oncology Precision Medicine: Market Opportunities

Figure 13.4 Oncology Precision Medicine: Market Challenges

Figure 14.1 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)

Figure 14.2 Global Oncology Precision Medicine Market, 2023-2035: Conservative Scenario (USD Billion)

Figure 14.3 Global Oncology Precision Medicine Market, 2023-2035: Optimistic Scenario (USD Billion)

Figure 15.1 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035

Figure 15.2 Oncology Precision Medicine Market for Bladder Cancer, 2023-2035 (USD Billion)

Figure 15.3 Oncology Precision Medicine Market for Blood / Hematologic Cancer, 2023-2035 (USD Billion)

Figure 15.4 Oncology Precision Medicine Market for Breast Cancer, 2023-2035 (USD Billion)

Figure 15.5 Oncology Precision Medicine Market for Cervical Cancer, 2023-2035 (USD Billion)

Figure 15.6 Oncology Precision Medicine Market for Gastrointestinal Cancer, 2023-2035 (USD Billion)

Figure 15.7 Oncology Precision Medicine Market for Head and Neck Squamous Cancer, 2023-2035 (USD Billion)

Figure 15.8 Oncology Precision Medicine Market for Lung Cancer, 2023-2035 (USD Billion)

Figure 15.9 Oncology Precision Medicine Market for Skin Cancer, 2023-2035 (USD Billion)

Figure 15.10 Oncology Precision Medicine Market for Other Cancers, 2023-2035 (USD Billion)

Figure 16.1 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035

Figure 16.2 Oncology Precision Medicine Market for Oral, 2023-2035 (USD Billion)

Figure 16.3 Oncology Precision Medicine Market for Intravenous, 2023-2035 (USD Billion)

Figure 16.4 Oncology Precision Medicine Market for Others, 2023-2035 (USD Billion)

Figure 17.1 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035

Figure 17.2 Oncology Precision Medicine Market for Small Molecules, 2023-2035 (USD Billion)

Figure 17.3 Oncology Precision Medicine Market for Biologics, 2023-2035, (USD Billion)

Figure 18.1 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035

Figure 18.2 Oncology Precision Medicine Market for Kinase Inhibitors, 2023-2035 (USD Billion)

Figure 18.3 Oncology Precision Medicine Market for Enzyme Inhibitors,2023-2035 (USD Billion)

Figure 18.4 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, 2023-2035 (USD Billion)

Figure 18.5 Oncology Precision Medicine Market for Others, 2023-2035 (USD Billion)

Figure 19.1 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035

Figure 19.2 Oncology Precision Medicine Market in North America, 2023-2035 (USD Billion)

Figure 19.3 Oncology Precision Medicine Market in the US, 2023-2035 (USD Billion)

Figure 19.4 Oncology Precision Medicine Market in Canada, 2023-2035 (USD Billion)

Figure 19.5 Oncology Precision Medicine Market in Europe, 2023-2035 (USD Billion)

Figure 19.6 Oncology Precision Medicine Market in France, 2023-2035 (USD Billion)

Figure 19.7 Oncology Precision Medicine Market in Germany, 2023-2035 (USD Billion)

Figure 19.8 Oncology Precision Medicine Market in Italy, 2023-2035 (USD Billion)

Figure 19.9 Oncology Precision Medicine Market in Spain, 2023-2035 (USD Billion)

Figure 19.10 Oncology Precision Medicine Market in UK, 2023-2035 (USD Billion)

Figure 19.11 Oncology Precision Medicine Market in Asia, 2023-2035 (USD Billion)

Figure 19.12 Oncology Precision Medicine Market in China, 2023-2035 (USD Billion)

Figure 19.13 Oncology Precision Medicine Market in Japan, 2023-2035 (USD Billion)

Figure 19.14 Oncology Precision Medicine Market in Korea, 2023-2035 (USD Billion)

Figure 19.15 Oncology Precision Medicine Market in India, 2023-2035 (USD Billion)

Figure 19.16 Oncology Precision Medicine Market in Middle East and North Africa, 2023-2035 (USD Billion)

Figure 19.17 Oncology Precision Medicine Market in UAE, 2023-2035 (USD Billion)

Figure 19.18 Oncology Precision Medicine Market in Israel, 2023-2035 (USD Billion)

Figure 19.19 Oncology Precision Medicine Market in Qatar, 2023-2035 (USD Billion)

Figure 19.20 Oncology Precision Medicine Market in Rest of Middle East and North Africa, 2023-2035 (USD Billion)

Figure 19.21 Oncology Precision Medicine Market in Latin America, 2023-2035 (USD Billion)

Figure 19.22 Oncology Precision Medicine Market in Brazil, 2023-2035 (USD Billion)

Figure 19.23 Oncology Precision Medicine Market in Israel, 2023-2035 (USD Billion)

Figure 19.24 Oncology Precision Medicine Market in Chile, 2023-2035 (USD Billion)

Figure 19.25 Oncology Precision Medicine Market in Rest of Latin America, 2023-2035 (USD Billion)

Figure 20.1 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRIS® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.2 Blockbuster Commercialized Oncology Precision Medicine Market: Alecensa® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.3 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIG® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.4 Blockbuster Commercialized Oncology Precision Medicine Market: Avastin® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.5 Blockbuster Commercialized Oncology Precision Medicine Market: Ayvakit® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.6 Blockbuster Commercialized Oncology Precision Medicine Market: Braftovi®+ Mektovi® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.7 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSA® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.8 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCE® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.9 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEX® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.10 Blockbuster Commercialized Oncology Precision Medicine Market: Elunate® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.11 Blockbuster Commercialized Oncology Precision Medicine Market: Empliciti® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.12 Blockbuster Commercialized Oncology Precision Medicine Market: Enhertu® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.13 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCE® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.14 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIG® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.15 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICA® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.16 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZI® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.17 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTA® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.18 Blockbuster Commercialized Oncology Precision Medicine Market: Keytruda® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.19 Blockbuster Commercialized Oncology Precision Medicine Market: Kadcyla® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.20 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMA® / KISPLYX® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.21 Blockbuster Commercialized Oncology Precision Medicine Market: Lumakras® / Lumykras® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.22 Blockbuster Commercialized Oncology Precision Medicine Market: Mekinist® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.23 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNX® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.24 Blockbuster Commercialized Oncology Precision Medicine Market: NINLARO® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.25 Blockbuster Commercialized Oncology Precision Medicine Market: Opdivo® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.26 Blockbuster Commercialized Oncology Precision Medicine Market: Padcev® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.27 Blockbuster Commercialized Oncology Precision Medicine Market: Piqray® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.28 Blockbuster Commercialized Oncology Precision Medicine Market: Sprycel® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.29 Blockbuster Commercialized Oncology Precision Medicine Market: Tabrecta® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.30 Blockbuster Commercialized Oncology Precision Medicine Market: Tagrisso® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.31 Blockbuster Commercialized Oncology Precision Medicine Market: Tasigna® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.32 Blockbuster Commercialized Oncology Precision Medicine Market: Tecentriq® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.33 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTA® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.34 Blockbuster Commercialized Oncology Precision Medicine Market: Verzenio® / Verzenios Sales Forecast, 2023-2035 (USD Billion)

Figure 20.35 Blockbuster Commercialized Oncology Precision Medicine Market: Xospata® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.36 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDI® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.37 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULA® Sales Forecast, 2023-2035 (USD Billion)

Figure 20.38 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, 2024-2035 (USD Billion)

Figure 20.39 NDA-filed Oncology Precision Medicine Market: Elunate® Sales Forecast, 2025-2035 (USD Billion)

Figure 20.40 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, 2030-2035 (USD Billion)

Figure 20.41 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, 2030-2035 (USD Billion)

Figure 20.42 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, 2030-2035 (USD Billion)

Figure 20.43 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, 2030-2035 (USD Billion)

Figure 20.44 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast, 2025-2035 (USD Billion)

Figure 20.45 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast by Type of Cancer Targeted, 2025-2035 (USD Billion)

Figure 20.46 Phase III Oncology Precision Medicine Market: Elunate® Regional Sales Forecast, 2025-2035 (USD Billion)

Figure 20.47 Phase III Oncology Precision Medicine Market: ORPATHYS® Sales Forecast, 2028-2035 (USD Billion)

Figure 20.48 Phase III Oncology Precision Medicine Market: ORPATHYS® Regional Sales Forecast, 2028-2035 (USD Billion)

Figure 20.49 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, 2025-2035 (USD Billion)

Figure 20.50 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, 2025-2035 (USD Billion)

Figure 20.51 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, 2025-2035 (USD Billion)

Figure 20.52 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, 2025-2035 (USD Billion)

Figure 20.53 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Regional Sales Forecast, 2025-2035 (USD Billion)

Figure 20.54 Phase III Oncology Precision Medicine Market: ZOLINZA® Sales Forecast, 2024-2035 (USD Billion)

Figure 20.55 Phase III Oncology Precision Medicine Market: ZOLINZA® Regional Sales Forecast, 2024-2035 (USD Billion)

Figure 21.1 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines in the year 2022 (USD Billion))

Figure 22.1 Conclusion: Market Landscape

Figure 22.2 Conclusion: Partnerships and Collaborations

Figure 22.3 Conclusion: Clinical Trial Analysis

Figure 22.4 Conclusion: Case Study Oncology Precision Medicine Assay Kits

Figure 22.5 Conclusion: Market Forecast and Opportunity Analysis

+ List of Tables

Table 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Developer, Brand, Stage of Development, Approval Body and Approval Region

Table 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Drug Designation

Table 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Molecule, Drug Class, Route of Administration, Dosage Regimen and Patient Population

Table 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Cancer Targeted

Table 6.5 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Developer and Stage of Development

Table 6.6 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Molecule and Drug Class

Table 6.7 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Cancer Targeted

Table 6.8 Oncology Precision Medicine: List of Developers

Table 7.1 Oncology Precision Medicine: List of Companies Profiled

Table 7.2 AstraZeneca: Company Snapshot

Table 7.3 AstraZeneca: Oncology Precision Medicine Portfolio

Table 7.4 AstraZeneca: Recent Developments and Future Outlook

Table 7.5 Genentech: Company Snapshot

Table 7.6 Genentech: Oncology Precision Medicine Portfolio

Table 7.7 Jiangsu Hengrui Pharmaceuticals: Company Snapshot

Table 7.8 Jiangsu Hengrui Pharmaceuticals: Oncology Precision Medicine Portfolio

Table 7.9 Johnson & Johnson Innovative Medicine: Company Snapshot

Table 7.10 Johnson & Johnson Innovative Medicine: Oncology Precision Medicine Portfolio

Table 7.11 Johnson & Johnson Innovative Medicine: Recent Developments and Future Outlook

Table 7.12 Novartis: Company Snapshot

Table 7.13 Novartis: Oncology Precision Medicine Portfolio

Table 7.14 Novartis: Recent Developments and Future Outlook

Table 7.15 Pfizer: Company Snapshot

Table 7.16 Pfizer: Oncology Precision Medicine Portfolio

Table 7.17 Pfizer: Recent Developments and Future Outlook

Table 7.18 SpringWorks Therapeutics: Company Snapshot

Table 7.19 SpringWorks Therapeutics: Oncology Precision Medicine Portfolio

Table 7.20 SpringWorks Therapeutics: Recent Developments and Future Outlook

Table 8.1 Oncology Precision Medicine: List of Companies Profiled

Table 8.2 Company Profile: AbbVie

Table 8.3 Company Profile: Anticancer Biosciences

Table 8.4 Company Profile: Astellas Pharma

Table 8.5 Company Profile: Bayer

Table 8.6 Company Profile: Blueprint Medicines

Table 8.7 Company Profile: Bristol Myers Squibb

Table 8.8 Company Profile: Eli Lilly

Table 8.9 Company Profile: Erasca

Table 8.10 Company Profile: GlaxoSmithKline

Table 8.11 Company Profile: Hutchmed

Table 8.12 Company Profile: IDEAYA Biosciences

Table 8.13 Company Profile: Merck

Table 8.14 Company Profile: Repare Therapeutics

Table 8.15 Company Profile: Roche

Table 8.16 Company Profile: Seagen

Table 8.17 Company Profile: Takeda Pharmaceutical

Table 8.18 Company Profile: VERAXA Biotech GmbH

Table 8.19 Company Profile: VRise Therapeutics

Table 9.1 Oncology Precision Medicine: List of Partnerships and Collaborations, 2018-2023

Table 9.2 Partnerships and Collaborations: Information on Drug Involved and Type of Cancer Targeted

Table 9.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)

Table 11.1 Oncology Precision Medicine Assay Kits: Information on Developer, Stage of Development, Regulatory Certification / Compliance and Regional Availability

Table 11.2 Oncology Precision Medicine Assay Kits: Information on Type of Test, Type of Sample, Principle of Biomarker Detection and Turn-around Time

Table 11.3 Oncology Precision Medicine Assay Kits: Information on Type of Cancer Targeted

Table 11.4 Oncology Precision Medicine Assay Kits: Information on End-user

Table 11.5 List of Oncology Precision Medicine Assay Kit Developers

Table 21.1 List of Leading Oncology Precision Medicine Developers

Table 23.1 Allarity Therapeutics: Company Snapshot

Table 23.2 Elephas: Company Snapshot

Table 24.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development

Table 24.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body

Table 24.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region

Table 24.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation

Table 24.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule

Table 24.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class

Table 24.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration

Table 24.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen

Table 24.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population

Table 24.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted

Table 24.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted

Table 24.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development

Table 24.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule

Table 24.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class

Table 24.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted

Table 24.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment

Table 24.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size

Table 24.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)

Table 24.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)

Table 24.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)

Table 24.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines

Table 24.22 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.23 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.24 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.25 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.26 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)

Table 24.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023

Table 24.28 Partnerships and Collaborations: Distribution by Type of Partnership

Table 24.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023

Table 24.30 Partnerships and Collaborations: Distribution by Type of Partner

Table 24.31 Partnerships and Collaborations: Distribution by Drug Involved

Table 24.32 Partnerships and Collaborations: Distribution by Type of Cancer Targeted

Table 24.33 Most Active Players: Distribution by Number of Partnerships

Table 24.34 Partnership and Collaborations: Local and International Agreements

Table 24.35 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements

Table 24.36 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023

Table 24.37 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023

Table 24.38 Clinical Trial Analysis: Distribution by Trial Phase

Table 24.39 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase

Table 24.40 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018–2023

Table 24.41 Clinical Trial Analysis: Distribution by Trial Status

Table 24.42 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018–2023

Table 24.43 Clinical Trial Analysis: Distribution by Target Patient Population

Table 24.44 Clinical Trial Analysis: Distribution by Patient Gender

Table 24.45 Clinical Trial Analysis: Distribution by Type of Cancer Targeted

Table 24.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Table 24.47 Clinical Trial Analysis: Distribution by Type of Trial Masking

Table 24.48 Clinical Trial Analysis: Distribution by Type of Intervention Model

Table 24.49 Clinical Trial Analysis: Distribution by Type of Intervention

Table 24.50 Clinical Trial Analysis: Distribution by Trial Purpose

Table 24.51 Leading Industry Players: Distribution by Number of Clinical Trials

Table 24.52 Leading Non-Industry Players: Distribution by Number of Clinical Trials

Table 24.53 Clinical Trial Analysis: Distribution of Clinical Trials by Geography

Table 24.54 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status

Table 24.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status

Table 24.56 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development

Table 24.57 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance

Table 24.58 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability

Table 24.59 Oncology Precision Medicine Assay Kits: Distribution by Type of Test

Table 24.60 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used

Table 24.61 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection

Table 24.62 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time

Table 24.63 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted

Table 24.64 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted

Table 24.65 Oncology Precision Medicine Assay Kits: Distribution by End-user

Table 24.66 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user

Table 24.67 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user

Table 24.68 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment

Table 24.69 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size

Table 24.70 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)

Table 24.71 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)

Table 24.72 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)

Table 24.73 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model

Table 24.74 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed

Table 24.75 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)

Table 24.76 Global Oncology Precision Medicine Market, 2023-2035: Conservative Scenario (USD Billion)

Table 24.77 Global Oncology Precision Medicine Market, 2023-2035: Optimistic Scenario (USD Billion)

Table 24.78 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035

Table 24.79 Oncology Precision Medicine Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.80 Oncology Precision Medicine Market for Blood / Hematologic Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.81 Oncology Precision Medicine Market for Breast Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.82 Oncology Precision Medicine Market for Cervical Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.83 Oncology Precision Medicine Market for Gastrointestinal Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.84 Oncology Precision Medicine Market for Head and Neck Squamous Cell Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.85 Oncology Precision Medicine Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.86 Oncology Precision Medicine Market for Skin Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.87 Oncology Precision Medicine Market for Other Cancers, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.88 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035

Table 24.89 Oncology Precision Medicine Market for Oral, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.90 Oncology Precision Medicine Market for Intravenous, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.91 Oncology Precision Medicine Market for Others, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.92 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035

Table 24.93 Oncology Precision Medicine Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.94 Oncology Precision Medicine Market for Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035, (USD Billion)

Table 24.95 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035

Table 24.96 Oncology Precision Medicine Market for Kinase Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.97 Oncology Precision Medicine Market for Enzyme Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.98 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.99 Oncology Precision Medicine Market for Others, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.100 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035

Table 24.101 Oncology Precision Medicine Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.102 Oncology Precision Medicine Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.103 Oncology Precision Medicine Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.104 Oncology Precision Medicine Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.105 Oncology Precision Medicine Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.106 Oncology Precision Medicine Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.107 Oncology Precision Medicine Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.108 Oncology Precision Medicine Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.109 Oncology Precision Medicine Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.110 Oncology Precision Medicine Market in Asia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.111 Oncology Precision Medicine Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.112 Oncology Precision Medicine Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.113 Oncology Precision Medicine Market in Korea, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.114 Oncology Precision Medicine Market in India, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.115 Oncology Precision Medicine Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.116 Oncology Precision Medicine Market in UAE, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.117 Oncology Precision Medicine Market in Israel, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.118 Oncology Precision Medicine Market in Qatar, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.119 Oncology Precision Medicine Market in Rest of Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.120 Oncology Precision Medicine Market in Latin America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.121 Oncology Precision Medicine Market in Brazil, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.122 Oncology Precision Medicine Market in Argentina, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.123 Oncology Precision Medicine Market in Chile, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.124 Oncology Precision Medicine Market in Rest of Latin America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.125 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRIS® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.126 Blockbuster Commercialized Oncology Precision Medicine Market: Alecensa® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.127 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIG® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.128 Blockbuster Commercialized Oncology Precision Medicine Market: Avastin® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.129 Blockbuster Commercialized Oncology Precision Medicine Market: Ayvakit® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.130 Blockbuster Commercialized Oncology Precision Medicine Market: Braftovi®+ Mektovi® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.131 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.132 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCE® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.133 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.134 Blockbuster Commercialized Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.135 Blockbuster Commercialized Oncology Precision Medicine Market: Empliciti® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.136 Blockbuster Commercialized Oncology Precision Medicine Market: Enhertu® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.137 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCE® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.138 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIG® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.139 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.140 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZI® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.141 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.142 Blockbuster Commercialized Oncology Precision Medicine Market: Keytruda® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.143 Blockbuster Commercialized Oncology Precision Medicine Market: Kadcyla® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.144 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMA® / KISPLYX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.145 Blockbuster Commercialized Oncology Precision Medicine Market: Lumakras® / Lumykras® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.146 Blockbuster Commercialized Oncology Precision Medicine Market: Mekinist® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.147 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.148 Blockbuster Commercialized Oncology Precision Medicine Market: NINLARO® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.149 Blockbuster Commercialized Oncology Precision Medicine Market: Opdivo® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.150 Blockbuster Commercialized Oncology Precision Medicine Market: Padcev® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.151 Blockbuster Commercialized Oncology Precision Medicine Market: Piqray® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.152 Blockbuster Commercialized Oncology Precision Medicine Market: Sprycel® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.153 Blockbuster Commercialized Oncology Precision Medicine Market: Tabrecta® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.154 Blockbuster Commercialized Oncology Precision Medicine Market: Tagrisso® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.155 Blockbuster Commercialized Oncology Precision Medicine Market: Tasigna® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.156 Blockbuster Commercialized Oncology Precision Medicine Market: Tecentriq® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.157 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.158 Blockbuster Commercialized Oncology Precision Medicine Market: Verzenio® / Verzenios Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.159 Blockbuster Commercialized Oncology Precision Medicine Market: Xospata® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.160 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDI® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.161 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

Table 24.162 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Billion)

Table 24.163 NDA-filed Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.164 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)

Table 24.165 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)

Table 24.166 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)

Table 24.167 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)

Table 24.168 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.169 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast by Type of Cancer Targeted, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.170 Phase III Oncology Precision Medicine Market: Elunate® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.171 Phase III Oncology Precision Medicine Market: ORPATHYS® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)

Table 24.172 Phase III Oncology Precision Medicine Market: ORPATHYS® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)

Table 24.173 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.174 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.175 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.176 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.177 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.178 Phase III Oncology Precision Medicine Market: ZOLINZA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.179 Phase III Oncology Precision Medicine Market: ZOLINZA® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)

Table 24.180 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines in the year 2022 (USD Billion))

+ List of Companies and Organizations

Please reach out to our team for more details.

Oncology Precision Medicine Market